Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXA8CU
|
||||
| Drug Name |
N*6*-Imidazol-1-yl-N*4*-(1H-indol-5-yl)-N*6*-(3-phenyl-propyl)-thieno[3,2-d]pyrimidine-4,6-diamine
|
||||
| Synonyms |
CHEMBL312818
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Formula |
C26H23N7S
|
||||
| Canonical SMILES |
C(CN(c1cc2ncnc(Nc3ccc4[nH]ccc4c3)c2s1)n5ccnc5)Cc6ccccc6
|
||||
| InChI |
InChI=1S/C26H23N7S/c1-2-5-19(6-3-1)7-4-13-33(32-14-12-27-18-32)24-16-23-25(34-24)26(30-17-29-23)31-21-8-9-22-20(15-21)10-11-28-22/h1-3,5-6,8-12,14-18,28H,4,7,13H2,(H,29,30,31)
|
||||
| InChIKey |
VTLQAHPWBDJOFR-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Epidermal growth factor receptor III | Target Info | [1] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| HIF-2-alpha transcription factor network | |||||
| S1P3 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| WikiPathways | Focal Adhesion | ||||
| Signaling by VEGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | URL: https://www.ebi.ac.uk/chembl/ The ChEMBL database in 2017 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.